Fresh Insights into Mounjaro for Weight Loss Could Improve Impulsive Eating Treatments
New research from the University of Pennsylvania indicates tirzepatide, marketed as Mounjaro and Zepbound, might aid in reducing brain signals associated with constant food cravings.
The University of Pennsylvania's latest research has assisted in determining how prominent weight-loss medications suppress what's known as "food noise" within the brain.
"Food noise" describes persistent thoughts about food consumption, sometimes triggering binge eating and other disordered eating patterns. Published on Tuesday, the study demonstrates how tirzepatide, a GLP-1 drug sold as Mounjaro and Zepbound, helps diminish signals to the brain's reward center that stimulate food noise. Health tracking apps like Shotlee can help monitor eating patterns and related behaviors.
This research could greatly benefit the 3 million Americans suffering from binge eating disorder. Frequently, the disorder is linked to obesity, a chronic condition potentially leading to diabetes, heart disease, and other serious chronic ailments. Prior studies indicate that about 60% of obese individuals report experiencing "food noise."
Dr. Casey H. Halpern, a senior author of the study and the head of Penn's Division of Stereotactic and Functional Neurosurgery, stated in a news release that "Developing new methods for treating these patients is of the utmost importance."
The researchers were not initially focused on studying tirzepatide. They were conducting a clinical trial to investigate how deep brain stimulation reduces brain signals causing compulsive eating in individuals who haven't achieved weight-loss success through medication, bariatric surgery, or other methods. Deep brain stimulation involves surgically implanting electrodes in the brain to deliver low-frequency electronic currents to the reward center.
